Email this article Herpesvirus infection following allogenic hematopoietic stem cell transplantation with TCRαβ and CD19 depletion: risk factors and outcome
- Authors: Bogoyavlenskaya A.A.1, Laberko A.L.1, Shelikhova L.N.1, Shekhovtsova Z.B.1, Balashov D.N.1, Voronin K.A.1, Kurnikova E.E.1, Boyakova E.V.1, Raykina E.V.1, Brilliantova V.V.1, Pirumova R.P.1, Maschan M.A.1
-
Affiliations:
- National Reseach Practicle Center of Pediatric, Oncology, and Immunology named after Dmitry Rogachev
- Issue: Vol 16, No 1 (2017)
- Pages: 10-21
- Section: Статьи
- Submitted: 10.08.2018
- Published: 10.02.2017
- URL: https://hemoncim.com/jour/article/view/76
- DOI: https://doi.org/10.24287/1726-1708-2017-16-1-10-21
- ID: 76
Cite item
Full Text
Abstract
In this study we evaluated incidence and risk factors of Herpesvirus infections – Cytomegalovirus (CMV) и Epstein–Barr (EBV) – in recipients of allogenic hematopoietic stem cell transplantation (alloHSCT) with TCRαβ and CD19 depletion of graft. The usage of this method results to graft preservation of non-alloreactive TCRgd lymphocytes, leading to decresed risks of graft versus host disease (GVHD) with adequate antiviral control. We estimated the outcomes of 182 HSCT from haploidentical and unrelated donors in patients younger than 23 years old with malignant anf nonmalignant disoders. The cumulative incidence (Cum Inc) of CMV infection was 51% (95% CI 44–60). By uni- and multivariate analyzes was found the significant influence on CMV-viremia of acute GVHD grade 2–4, recipient’s seropositivity before HSCT and patient’s malignant disoder. Cum Inc of EBV infection was 33% (95% CI 26–42). The risk factor of EBV viremia was acute GVHD grade 2–4. The incidence of CMV-disease was 6% (11 patients), EBV-related posttransplant lymphoproliferative disoder (PTLD) 0,5% (1 patient). CMV and EBV viremia did not decrease survival after HSCT.
TCRαβ and CD19 depletion of graft was associated with significant risk of CMV viremia in patients after alloHSCT, but did not influence survival and transplant related mortality, and with extremely low risk of PTLD development.
About the authors
A. A. Bogoyavlenskaya
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Author for correspondence.
Email: analecs@gmail.com
MD, hematologist, Department of hematopoietic stem cell Transfusion
Russia 117997, Moscow, Samory Mashela st., 1
Tel.: +7 (495) 287-6570, ext. 7537
Russian FederationA. L. Laberko
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
L. N. Shelikhova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
Z. B. Shekhovtsova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
D. N. Balashov
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
K. A. Voronin
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
E. E. Kurnikova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
E. V. Boyakova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
E. V. Raykina
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
V. V. Brilliantova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
R. P. Pirumova
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
M. A. Maschan
National Reseach Practicle Center of Pediatric,Oncology, and Immunology named after Dmitry Rogachev
Russian Federation
References
Supplementary files
